Cargando…
Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders
Psychobiotics are a group of probiotics that affect the central nervous system (CNS) related functions and behaviors mediated by the gut-brain-axis (GBA) via immune, humoral, neural, and metabolic pathways to improve not only the gastrointestinal (GI) function but also the antidepressant and anxioly...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Food and Drug Administration
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307042/ https://www.ncbi.nlm.nih.gov/pubmed/31324280 http://dx.doi.org/10.1016/j.jfda.2019.01.002 |
_version_ | 1784752680993816576 |
---|---|
author | Cheng, Li-Hao Liu, Yen-Wenn Wu, Chien-Chen Wang, Sabrina Tsai, Ying-Chieh |
author_facet | Cheng, Li-Hao Liu, Yen-Wenn Wu, Chien-Chen Wang, Sabrina Tsai, Ying-Chieh |
author_sort | Cheng, Li-Hao |
collection | PubMed |
description | Psychobiotics are a group of probiotics that affect the central nervous system (CNS) related functions and behaviors mediated by the gut-brain-axis (GBA) via immune, humoral, neural, and metabolic pathways to improve not only the gastrointestinal (GI) function but also the antidepressant and anxiolytic capacity. As a novel class of probiotics, the application of psychobiotics has led researchers to focus on a new area in neuroscience. In the past five years, some psychobiotics strains were reported to inhibit inflammation and decreased cortisol levels, resulting in an amelioration of the symptoms of anxiety and depression. Psychobiotics are efficacious in improving neurodegenerative and neurodevelopmental disorders, including autism spectrum disorder (ASD), Parkinson’s disease (PD) and Alzheimer’s disease (AD). Use of psychobiotics can improve GI function, ASD symptoms, motor functions of patients with PD and cognition in patients with AD. However, the evidence for the effects of psychobiotics on mental and neurological conditions/ disorders remains limited. Further studies of psychobiotics are needed in order to determine into their effectiveness and mechanism as treatments for various psychiatric disorders in the future. |
format | Online Article Text |
id | pubmed-9307042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taiwan Food and Drug Administration |
record_format | MEDLINE/PubMed |
spelling | pubmed-93070422022-08-09 Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders Cheng, Li-Hao Liu, Yen-Wenn Wu, Chien-Chen Wang, Sabrina Tsai, Ying-Chieh J Food Drug Anal Review Article Psychobiotics are a group of probiotics that affect the central nervous system (CNS) related functions and behaviors mediated by the gut-brain-axis (GBA) via immune, humoral, neural, and metabolic pathways to improve not only the gastrointestinal (GI) function but also the antidepressant and anxiolytic capacity. As a novel class of probiotics, the application of psychobiotics has led researchers to focus on a new area in neuroscience. In the past five years, some psychobiotics strains were reported to inhibit inflammation and decreased cortisol levels, resulting in an amelioration of the symptoms of anxiety and depression. Psychobiotics are efficacious in improving neurodegenerative and neurodevelopmental disorders, including autism spectrum disorder (ASD), Parkinson’s disease (PD) and Alzheimer’s disease (AD). Use of psychobiotics can improve GI function, ASD symptoms, motor functions of patients with PD and cognition in patients with AD. However, the evidence for the effects of psychobiotics on mental and neurological conditions/ disorders remains limited. Further studies of psychobiotics are needed in order to determine into their effectiveness and mechanism as treatments for various psychiatric disorders in the future. Taiwan Food and Drug Administration 2019-02-10 /pmc/articles/PMC9307042/ /pubmed/31324280 http://dx.doi.org/10.1016/j.jfda.2019.01.002 Text en © 2019 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Review Article Cheng, Li-Hao Liu, Yen-Wenn Wu, Chien-Chen Wang, Sabrina Tsai, Ying-Chieh Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
title | Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
title_full | Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
title_fullStr | Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
title_full_unstemmed | Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
title_short | Psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
title_sort | psychobiotics in mental health, neurodegenerative and neurodevelopmental disorders |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307042/ https://www.ncbi.nlm.nih.gov/pubmed/31324280 http://dx.doi.org/10.1016/j.jfda.2019.01.002 |
work_keys_str_mv | AT chenglihao psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders AT liuyenwenn psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders AT wuchienchen psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders AT wangsabrina psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders AT tsaiyingchieh psychobioticsinmentalhealthneurodegenerativeandneurodevelopmentaldisorders |